Serial No.: 10/593,010 Case No.: 21584P Page No.: 2

#### **Amendments to the Claims**

1.- 15. (Canceled)

16. (Withdrawn) A compound of structural formula II:

$$R^{8}$$
 $R^{9}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{3}$ 

or a pharmaceutically acceptable salt thereof; wherein

each n is 0, 1, or 2;

each p is 0, 1, or 2;

R<sup>8</sup> is naphthyl or heteroaryl wherein heteroaryl is selected from the group consisting of

pyridyl,

thienyl,

furyl,

pyrazolyl,

thiazolyl,

oxazolyl,

imidazolyl,

indolyl,

benzothiophenyl,

benzofuryl, and

benzimidazolyl;

in which naphthyl and heteroaryl are substituted with one to three substituents independently selected from R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup>;

R<sup>2</sup> is methyl or cyclopropyl;

R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are each independently selected from the group consisting of

hydrogen,

formyl,

C<sub>1-6</sub> alkyl,

C<sub>2-6</sub> alkenyl,

(CH<sub>2</sub>)<sub>n</sub>-aryl,

(CH<sub>2</sub>)<sub>n</sub>-heteroaryl,

Serial No.: 10/593,010 Case No.: 21584P Page No.: 3

```
(CH_2)_n-heterocyclyl,
(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-7 cycloalkyl,
halogen,
OR^7,
(CH_2)_nN(R^7)_2,
cyano,
(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>7</sup>,
NO<sub>2</sub>,
(CH_2)_nNR^7SO_2R^6,
(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>N(R<sup>7</sup>)<sub>2</sub>,
(CH_2)_nS(O)_pR^6,
(CH_2)_nSO_2OR^7,
(CH_2)_nNR^7C(O)N(R^7)_2,
(CH_2)_nC(O)N(R^7)_2,
(CH_2)_nNR^6C(O)R^6,
(CH<sub>2</sub>)<sub>n</sub>NR<sup>6</sup>CO<sub>2</sub>R<sup>7</sup>,
O(CH_2)_nC(O)N(R^7)_2
CF3,
CH<sub>2</sub>CF<sub>3</sub>,
OCF<sub>3</sub>,
OCHCF2, and
OCH2CF3;
```

wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C<sub>1-4</sub> alkyl, trifluoromethyl, trifluoromethoxy, and C<sub>1-4</sub> alkoxy; and wherein any methylene (CH<sub>2</sub>) carbon atom in R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl; or two substituents when on the same methylene (CH<sub>2</sub>) carbon atom are taken together with the carbon atom to which they are attached to form a cyclopropyl group;

each R6 is independently selected from the group consisting of

C<sub>1-8</sub> alkyl, (CH<sub>2</sub>)<sub>n</sub>-aryl, (CH<sub>2</sub>)<sub>n</sub>-heteroaryl, and (CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-7 cycloalkyl;

wherein alkyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, oxo, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, hydroxy, amino; and

10/593,010

21584P

Serial No.:

Case No.:

Page No.:

aryl and heteroaryl are unsubstituted or substituted with one to three substituents independently selected from cyano, halogen, hydroxy, amino, carboxy, trifluoromethyl, trifluoromethoxy, C<sub>1-4</sub> alkyl, and C<sub>1-4</sub> alkoxy;

or two  $R^6$  groups together with the atom to which they are attached form a 5- to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and  $NC_{1-4}$  alkyl; and

each R<sup>7</sup> is hydrogen or R<sup>6</sup>.

- 17. (Withdrawn) The compound of Claim 16 wherein R<sup>2</sup> is methyl.
- 18. (Withdrawn) The compound of Claim 16 wherein R<sup>8</sup> is indolyl or pyrazolyl substituted with one to three substituents independently selected from R<sup>3</sup>.
  - 19. (Withdrawn) The compound of Claim 18 wherein R<sup>2</sup> is methyl.
  - 20. (Withdrawn) A compound which is selected from the group consisting of:
- 4-methyl-3,5-bis[2-(trifluoromethyl)phenyl]-4*H*-1,2,4-triazole;
- 4-methyl-3-[4-(methylthio)-2-(trifluoromethyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-4*H*-1,2,4-triazole;
- 4-methyl-3-(4-pentylphenyl)-5-[2-(trifluoromethyl)phenyl]-4*H*-1,2,4-triazole;
- 3-(2-chlorophenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4*H*-1,2,4-triazole;
- 3-(1-methoxy-2-naphthyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4*H*-1,2,4-triazole;
- 4-[5-(2-chlorophenyl)-4-methyl-4*H*-1,2,4-triazol-3-yl]-1-methyl-1*H*-indole;
- $4-\{4-\text{methyl}-5-[2-(\text{trifluoromethyl})\text{phenyl}]-4H-1,2,4-\text{triazol}-3-\text{yl}\}-1-\text{methyl}-1H-\text{indole};$
- 3-(2-bromophenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4*H*-1,2,4-triazole;
- 3-(7-chloro-1-methoxy-2-naphthyl)-4-methyl-5-[2-(trifluoromethyl)-4*H*-1,2,4-triazole;
- 4-[4-methyl-5-(1-methyl-1*H*-indol-4-yl)-4*H*-1,2,4-triazol-3-yl]phenol;
- 3-(2,4-dichlorophenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4*H*-1,2,4-triazole;
- 3-[2,4-bis(trifluoromethyl)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
- 3-(2-chlorophenyl)-5-(2,4-dichlorophenyl)-4-methyl-4*H*-1,2,4-triazole;
- 3-(2-chloro-4-fluorophenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
- 3-(2,4-dichlorophenyl)-4-methyl-5-[2-(methylthio)phenyl]-4H-1,2,4-triazole;
- 3-(2,4-dichlorophenyl)-4-methyl-5-(2-methylphenyl)-4*H*-1,2,4-triazole;
- 3-(2-chlorophenyl)-5-[5-(2-chlorophenyl)-1-methyl-1*H*-pyrazol-3-yl]-4-methyl-4*H*-1,2,4-triazole:
- 4-[5-(2-methoxyphenyl)-4-methyl-4H-1,2,4-triazol-3-yl]-1-methyl-1H-indole;
- 4-methyl-3-(2-methyl-1-naphthyl)-5-[2-(trifluoromethyl)phenyl]-4-methyl-4*H*-1,2,4-triazole;

# DO NOT ENTER /PEZ/

10/593,010

21584P

Serial No.:

Case No.:

Page No.:

12/24/2009

```
3-(1,4-dichloro-2-naphthyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-(4-chloro-1-methoxy-2-naphthyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-(1-fluoro-2-naphthyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
N-methyl-2-{4-methyl-5-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}naphthalen-1-amine;
3,5-bis-(2,4-dimethylphenyl)-4-methyl-4H-1,2,4-triazole;
3-(2,4-dichlorophenyl)-5-[2-(ethylthio)phenyl]-4-methyl-4H-1,2,4-triazole;
3-(2-cyclopropylphenyl)-5-(2,4-dichlorophenyl)-4-methyl-4H-1,2,4-triazole;
3-[(2-chloro-4-(ethylthio)phenyl)]-5-(2-fluorophenyl)-4-methyl-4H-1,2,4-triazole;
3-(2-methoxyphenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-(2,6-dichlorophenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-(2-chlorophenyl)-5-[(2-difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazole;
3-(2-chloro-4-fluorophenyl)-5-(2-chlorophenyl)-4-methyl-4H-1,2,4-triazole;
3-(2.4-dichlorophenyl)-5-[(2-difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazole;
4-methyl-3-(2-phenoxyphenyl)-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
4-methyl-3-[2-(trifluoromethoxy)phenyl]-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
4-methyl-3-[2-(prop-2-yn-1-yloxy)phenyl]-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-{2-[(4-chlorophenyl)thio]phenyl}-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-[2-(difluoromethoxy)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-(2-ethoxyphenyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
4-methyl-3-(2-propoxyphenyl)-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3,5-bis(2-chlorophenyl)-4-methyl-4H-1,2,4-triazole;
3,5-bis(2,3-dichlorophenyl)-4-methyl-4H-1,2,4-triazole;
3-(3-chloro-2-naphthyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-(5-chloro-6-methoxy-1-naphthyl)-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-[2-(4-chlorophenoxy)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-[4-(4-chlorophenoxy)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-[4-chloro-5-(2-chlorophenyl)-1-methyl-1H-pyrazol-3-yl]-4-methyl-5-[2-
(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
4-methyl-3-(2,4,6-trichloro-1-naphthyl)-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;
3-(2-chlorophenyl)-4-methyl-5-[2-(trifluoromethoxy)phenyl]-4H-1,2,4-triazole;
3-(2-bromophenyl)-5-(2-methoxyphenyl)-4-methyl-4H-1,2,4-triazole;
3-(2,3-dichlorophenyl)-4-methyl-5-(2-methylphenyl)-4H-1,2,4-triazole;
3-(2,3-dichlorophenyl)-5-(2-methoxyphenyl)-4-methyl-4H-1,2,4-triazole;
3-(2-bromophenyl)-4-methyl-5-(2-methylphenyl)-4H-1,2,4-triazole;
```

3-(2-chlorophenyl)-4-cyclopropyl-5-[(2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole;

4-methyl-3-(2-methylphenyl)-5-[2-(trifluoromethoxyl)phenyl]-4H-1,2,4-triazole;

### DO NOT ENTER /PEZ/

10/593,010

21584P

Serial No.:

Case No.:

Page No.:

12/24/2009

3-(4-chloro-3-methoxy-2-naphthyl)-4-methyl-5-[(2-(methylthio)phenyl]-4*H*-1,2,4-triazole;

3-[2-(4-chlorophenoxy)phenyl]-4-methyl-5-[(2-(methylthio)phenyl]-4*H*-1,2,4-triazole;

3-[2-(4-chlorophenoxy)phenyl]-4-methyl-5-[(2-(methylsulfonyl)phenyl]-4*H*-1,2,4-triazole;

3-(2-chlorophenyl)-5-(2,3-dichlorophenyl)-4-methyl-4*H*-1,2,4-triazole;

3-(2-bromophenyl)-5-(2-chlorophenyl)-4-methyl-4*H*-1,2,4-triazole;

3-[2-(4-fluorophenoxy)phenyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-4*H*-1,2,4-triazole;

3-(2-chlorophenyl)-5-[2-chloro-3-(trifluoromethyl)phenyl]-4-methyl-4H-1,2,4-triazole; and

4-[4-methyl-5-(1,2,3-trimethyl-1*H*-indol-5-yl)-4*H*-1,2,4-triazol-3-yl]phenol;

or a pharmaceutically acceptable salt thereof.

- 21. (Withdrawn) A pharmaceutical composition comprising a compound in accordance with Claim 16 in combination with a pharmaceutically acceptable carrier.
- 22. (Withdrawn) A pharmaceutical composition comprising a compound in accordance with Claim 20 in combination with a pharmaceutically acceptable carrier.
- 23. (New) A compound of structural formula I or a pharmaceutically acceptable salt thereof useful for treating a condition responsive to inhibition of  $11\beta$ -hydroxysteroid dehydrogenase-1 in a mammal in need thereof

$$R^{1} \xrightarrow{N-N} R^{5}$$

$$R^{2} \xrightarrow{R^{3}} R^{3}$$

$$(I)$$

wherein

each n is 0, 1, or 2;

each p is 0, 1, or 2;

R<sup>1</sup> is anylor heteroaryl wherein heteroaryl is selected from the group consisting of

pyridyl,

thienyl,

furyl,

pyrazolyl,

thiazolyl,

oxazolyl,

imidazolyl,

indolyl,

benzothiophenyl,

benzofuryl, and

benzimidazolyl;

in which aryl and heteroaryl are substituted with one to four substituents independently selected from R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup>;

R<sup>2</sup> is methyl;

# DO NOT ENTER /PEZ/

12/24/2009

10/593,010

21584P

Serial No.:

Case No.:

Page No.:

R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are each independently selected from the group consisting of hydrogen, formyl, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, (CH<sub>2</sub>)<sub>n</sub>-aryl,(CH<sub>2</sub>)<sub>n</sub>-heteroaryl, (CH<sub>2</sub>)<sub>n</sub>-heterocyclyl, (CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-7 cycloalkyl, halogen,  $OR^7$ ,  $(CH_2)_nN(R^7)_2$ , cyano, (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>7</sup>,NO2, (CH<sub>2</sub>)<sub>n</sub>NR<sup>7</sup>SO<sub>2</sub>R<sup>6</sup>,  $(CH_2)_nSO_2N(R^7)_2$ ,  $(CH_2)_nS(O)_nR^6$ , (CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>OR<sup>7</sup>,(CH<sub>2</sub>)<sub>n</sub>NR<sup>7</sup>C(O)N(R<sup>7</sup>)<sub>2</sub>, $(CH_2)_nC(O)N(R^7)_2$ , (CH<sub>2</sub>)<sub>n</sub>NR<sup>6</sup>C(O)R<sup>6</sup>,  $(CH_2)_nNR^6CO_2R^7$ ,  $O(CH_2)_nC(O)N(R^7)_2$ CF3, CH<sub>2</sub>CF<sub>3</sub>, OCF<sub>3</sub>, OCHCF2, and OCH2CF3;

wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, C<sub>1-4</sub> alkyl, trifluoromethyl, trifluoromethoxy, and C<sub>1-4</sub> alkoxy; and wherein any methylene (CH<sub>2</sub>) carbon atom in R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl; or two substituents when on the same methylene (CH<sub>2</sub>) carbon atom are taken together with the carbon atom to which they are attached to form a cyclopropyl group;

```
each R6 is independently selected from the group consisting of
```

C<sub>1-8</sub> alkyl, C<sub>2-4</sub> alkynyl, (CH<sub>2</sub>)<sub>n</sub>-aryl, (CH<sub>2</sub>)<sub>n</sub>-heteroaryl, and

Serial No.: 10/593,010 Case No.: 21584P Page No.: 8

#### $(CH_2)_nC_3$ -7 cycloalkyl;

wherein alkyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, oxo, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, hydroxy, and amino; and aryl and heteroaryl are unsubstituted or substituted with one to three substituents independently selected from cyano, halogen, hydroxy, amino, carboxy, trifluoromethyl, trifluoromethoxy, C<sub>1-4</sub> alkyl, and C<sub>1-4</sub> alkoxy;

or two  $R^6$  groups together with the atom to which they are attached form a 5- to 8-membered mono- or bicyclic ring system optionally containing an additional heteroatom selected from O, S, and  $NC_{0-4}$  alkyl;

each  $R^7$  is hydrogen or  $R^6$ ; and

wherein the compound of structural formula I is selected from the group consisting of:

DO NOT ENTER Serial No.: 10/593,010

/PEZ/ Case No.: 21584P

Page No.: 9

12/24/2009

CF<sub>3</sub> N-N